iCAD Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

iCAD wird ein Gewinn- und Umsatzwachstum von 18.3% bzw. 18.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 22.2% pro Jahr wachsen soll.

Wichtige Informationen

18.3%

Wachstumsrate der Gewinne

22.2%

EPS-Wachstumsrate

Healthcare Services Gewinnwachstum	30.9%
Wachstumsrate der Einnahmen	18.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Aug 21

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

Jun 27

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Feb 29

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ICAD - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	29	-3	N/A	N/A	2
12/31/2025	24	-6	N/A	N/A	2
12/31/2024	19	-7	N/A	N/A	3
6/30/2024	19	-5	-5	-4	N/A
3/31/2024	18	-5	-6	-5	N/A
12/31/2023	17	-7	-6	-5	N/A
9/30/2023	17	-9	-7	-7	N/A
6/30/2023	18	-11	-8	-8	N/A
3/31/2023	17	-9	-10	-10	N/A
12/31/2022	20	-10	-13	-13	N/A
9/30/2022	23	-12	-12	-11	N/A
6/30/2022	28	-11	-11	-11	N/A
3/31/2022	33	-13	-11	-10	N/A
12/31/2021	34	-11	-10	-9	N/A
9/30/2021	36	-9	-9	-9	N/A
6/30/2021	34	-8	-10	-9	N/A
3/31/2021	32	-7	-10	-9	N/A
12/31/2020	30	-18	-7	-7	N/A
9/30/2020	29	-19	-9	-8	N/A
6/30/2020	29	-21	-9	-8	N/A
3/31/2020	31	-22	-7	-7	N/A
12/31/2019	31	-14	-7	-7	N/A
9/30/2019	29	-14	-7	-6	N/A
6/30/2019	27	-12	-5	-5	N/A
3/31/2019	26	-9	-5	-5	N/A
12/31/2018	26	-9	-4	-4	N/A
9/30/2018	27	-10	-4	-4	N/A
6/30/2018	27	-15	-6	-6	N/A
3/31/2018	28	-17	N/A	-6	N/A
12/31/2017	28	-14	N/A	-7	N/A
9/30/2017	27	-13	N/A	-7	N/A
6/30/2017	26	-9	N/A	-6	N/A
3/31/2017	27	-8	N/A	-5	N/A
12/31/2016	26	-10	N/A	-5	N/A
9/30/2016	27	-9	N/A	-6	N/A
6/30/2016	31	-7	N/A	-5	N/A
3/31/2016	34	-33	N/A	-4	N/A
12/31/2015	42	-32	N/A	-2	N/A
9/30/2015	48	-30	N/A	3	N/A
6/30/2015	50	-29	N/A	6	N/A
3/31/2015	49	-3	N/A	5	N/A
12/31/2014	44	-1	N/A	3	N/A
9/30/2014	39	-5	N/A	2	N/A
6/30/2014	35	-6	N/A	-3	N/A
3/31/2014	33	-7	N/A	-2	N/A
12/31/2013	33	-8	N/A	-1	N/A
9/30/2013	31	-6	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ICAD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ICAD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ICAD wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ICADDie Einnahmen des Unternehmens (18.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: ICADDie Einnahmen des Unternehmens (18.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ICAD in 3 Jahren voraussichtlich hoch sein wird

iCAD Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus EPS estimates fall by 18%, revenue upgraded

Forecast to breakeven in 2026

No longer forecast to breakeven

Consensus revenue estimates fall by 12%

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 16%

Recent updates

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% But Many Are Still Ignoring The Company

Consensus EPS estimates fall by 18%, revenue upgraded

New major risk - Revenue and earnings growth

iCAD, Inc. to Report Q2, 2024 Results on Aug 13, 2024

iCAD, Inc.'s (NASDAQ:ICAD) P/S Still Appears To Be Reasonable

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Forecast to breakeven in 2026

iCAD, Inc. to Report Q1, 2024 Results on May 15, 2024

iCAD, Inc., Annual General Meeting, Jun 13, 2024

No longer forecast to breakeven

iCAD, Inc. Showcases New Profound Cloud, Enhanced Profound Detection Workstation Features at SBI Annual Symposium

iCAD, Inc. Announces Commercial Availability of ProFound Cloud

Consensus revenue estimates fall by 12%

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

iCAD, Inc. (NASDAQ:ICAD) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

iCAD, Inc. to Report Q4, 2023 Results on Mar 12, 2024

iCAD, Inc. Appoints Michael John Doyle to its Board of Directors

Forecast to breakeven in 2026

iCAD, Inc. Expands Executive Sales Leadership Team as Business Grows

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

iCAD, Inc. to Present New Studies Valuating its Artificial Intelligence Powered ProFound Breast Health Suite

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 16%

iCAD, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Profitability

Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD).

We're Hopeful That iCAD (NASDAQ:ICAD) Will Use Its Cash Wisely

Consensus EPS estimates upgraded to US$0.37 loss, revenue downgraded

Health Canada Grants Device License for iCAD's Profound Risk 2.0, Revolutionizing Breast Cancer Risk Via A 1-2 Year Assessment

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

iCAD, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Price target increased by 10% to US$4.88

We Think iCAD (NASDAQ:ICAD) Needs To Drive Business Growth Carefully

Consensus EPS estimates fall by 22%

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Executive Chair recently bought US$52k worth of stock

No longer forecast to breakeven

Price target decreased by 38% to US$5.08

Will iCAD (NASDAQ:ICAD) Spend Its Cash Wisely?

iCAD, Inc. Appoints Bill Keyes as Senior Vice President, US Commercial Sales, AI

iCAD, Inc. Appoints Dana Brown as Executive Chair of the Board of Directors

iCAD, Inc. Announces Nathaniel Dalton's Resignation from His Position as A Member of the Board

Consensus revenue estimates fall by 11%

Price target decreased to US$8.17

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Is iCAD (NASDAQ:ICAD) In A Good Position To Invest In Growth?

iCAD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Consensus revenue estimates fall by 15%

Forecast to breakeven in 2024

iCAD, Inc. to Report Q2, 2022 Results on Aug 10, 2022

iCAD, Inc.(NasdaqCM:ICAD) dropped from Russell 2000 Dynamic Index

Companies Like iCAD (NASDAQ:ICAD) Are In A Position To Invest In Growth

iCad, Inc. Announces CFO Changes

Icad, Inc. Announces Chief Financial Officer Changes

Icad, Inc. Announces That New Research Supporting Profound Ai for Digital Breast Tomosynthesis

iCAD, Inc. Announces Promising Clinical Research Supporting Profound Ai(R) Risk for Digital Breast Tomosynthesis

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

iCAD, Inc., Annual General Meeting, Jun 17, 2022

iCAD Announces Significant Commercial Momentum for ProFound AI Among Customers Equipped with the Provider of 3D Mammography Systems

No longer forecast to breakeven

iCAD, Inc. Announces Board Changes

iCAD, Inc. Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy for Brain, Rectal, Head and Neck Tumor Treatment

Consensus EPS estimates fall by 71%

Full year 2021 earnings: EPS exceeds analyst expectations

iCAD (NASDAQ:ICAD) Is In A Good Position To Deliver On Growth Plans

iCAD, Inc. to Report Q4, 2021 Results on Feb 28, 2022